Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers

Inclusion Criteria: * Healthy male subjects based on a complete medical history, physical examination, vital signs (blood pressure and pulse rate), 12-lead ECG, and clinical laboratory tests * Age of 18 to 50 years * Body mass index (BMI) of 18.5 to 29.9 kg/m2 * Signed and dated written informed consent in accordance with Good Clinical Practice and the local legislation Exclusion Criteria: * Any clinically relevant deviation from normal in the medical examination including blood pressure, pulse rate, and ECG * Any evidence of a clinically relevant concomitant disease * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders * Surgery of the gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy), psychiatric disorders, or neurological disorders * History of relevant orthostatic hypotension, fainting spells, or blackouts * Chronic or relevant acute infections * History of relevant allergy or hypersensitivity (including allergy to drug or its excipients) * Intake of drugs with a long half-life (\>24 h) within at least 1 month or less than 10 half-lives of the respective drug before first treatment with study drug or during trial * Use of drugs which might reasonably influence the results of the trial or which prolong the QT/QTc interval within 10 days before first treatment with study drug or during trial * Participation in another trial with an investigational drug within 30 days before first treatment with study drug or during trial * Smoker (more than 10 cigarettes, 3 cigars, or 3 pipes per day) * Inability to refrain from smoking beginning from 1 day before first treatment with study drug until discharge from the clinical unit * Alcohol abuse (more than 60 grams per day) * Drug abuse * Blood donation of more than 100 mL within 4 weeks before first treatment with study drug or during trial * Excessive physical activities within 1 week before first treatment with study drug or during trial * Any laboratory value outside the reference range and of clinical relevance * Inability to comply with dietary regimen of trial site * A marked baseline prolongation of the QT/QTc interval (e.g. QTc intervals that are repeatedly longer than 450 ms) * A history of additional risk factors for torsades de points (e.g. heart failure, hypokalaemia, or family history of Long QT syndrome